未找到相关数据
ClarIDHy: A phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation.
被引：3
作者：
Abou-Alfa, Ghassan K.
Valle, Juan W.
Kelley, Robin Kate
Goyal, Lipika
Shroff, Rachna T.
Javle, Milind M.
Borad, Mitesh J.
Cleary, James M.
El-Khoueiry, Anthony B.
Bendell, Johanna C.
Macarulla, Teresa Mercade
Vogel, Arndt
Korth, Christopher
Jiang, Liewen
Gliser, Camelia
Bin Wu
Agresta, Samuel V.
Pandya, Shuchi Sumant
Zhu, Andrew X.
机构：
[1] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Univ Manchester Inst Canc Sci, Manchester, Lancs, England
[3] Univ Calif San Francisco, San Francisco, CA USA
[4] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[6] Mayo Clin, Scottsdale, AZ USA
[7] Dana Farber Canc Inst, Boston, MA USA
[8] USC Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[9] Sarah Cannon Res Inst, Nashville, TN USA
[10] Vall Hebron Univ Hosp, Inst Oncol, Barcelona, Spain
[11] Hannover Med Sch, Hannover, Germany
[12] Agios Pharmaceut Inc, Cambridge, MA USA
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.TPS545
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS545
引用
收藏
页数：1
相关论文